Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	8.91T +272.6%
Revenue (ttm)	5.08B +0.2%
Net Income	-87.46B
EPS	-1,074.77
Shares Out	83.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590,993
Average Volume	543,781
Open	105,000
Previous Close	105,000
Day's Range	102,000 - 111,900
52-Week Range	31,250 - 111,900
Beta	-0.67
RSI	67.24
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.